Table 1.
Engineered bacterial therapeutics currently in clinical development.
| Engineered bacterial therapeutic | Chassis organism | Therapeutic indication | Sponsor | Phase of development |
|---|---|---|---|---|
| AG013 | Lactococcus lactis | Oral mucositis | Oragenics | Phase 2b |
| AG014 | Lactococcus lactis | Gastrointestinal Inflammation in Primary Immunodeficiency | ActoBio Therapeutics | Phase 1 |
| AG019 | Lactococcus lactis | Type 1 Diabetes Mellitus | ActoBio Therapeutics | Phase 1b/2a |
| ADXS-HOT | Lysteria monocytogenes | Non-Small Cell Lung Cancer | Advaxis Immunotherapies | Phase 1 |
| ADXS-HPV | Lysteria monocytogenes | HPV-Associated Cancers | Advaxis Immunotherapies | Phase 1/2 |
| ADXS-PA | Lysteria monocytogenes | Metastatic Prostate Cancer | Advaxis Immunotherapies | Phase 2 |
| APS001F | Bifidobacterium longum | Solid Tumors | Anaeropharma Science | Phase 1 |
| AZT-04 | Staphylococcus epidermidis | Cancer Therapy-associated Rashes | Azitra | Phase 1 |
| bacTRL-IL-12 | Bifidobacterium longum | Solid Tumors | Symvivo | Phase 1 |
| SYNB1020 | E. coli Nissle 1917 | Hyperammonemia | Synlogic | Discontinued |
| SYNB1618 | E. coli Nissle 1917 | Phenylketonuria (PKU) | Synlogic | Phase 1/2a |
| SYNB1891 | E. coli Nissle 1917 | Solid Tumors | Synlogic | Phase 1 |
| VXM01 | Salmonella Typhi Ty21a | Progressive Glioblastoma | VAXIMM | Phase 2 |
List of engineered bacterial therapeutics in clinical development, describing the chassis organism, therapeutic indication, and the organization sponsoring development.